Regeneron Pharmaceuticals, Inc. (REGN)
| Previous close | 608.24 |
| Open | 601.11 |
| Bid | 598.60 x 1300 |
| Ask | 599.60 x 1400 |
| Day's range | 592.45 - 608.23 |
| 52-week range | 271.37 - 664.64 |
| Volume | 70,037 |
| Avg. volume | 1,233,564 |
| Market cap | 63.75B |
| Beta (5Y monthly) | 0.55 |
| PE ratio (TTM) | 23.20 |
| EPS (TTM) | 25.83 |
| Earnings date | 03 Nov 2020 - 09 Nov 2020 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 673.84 |
- Editor's pickYahoo Finance
Coronavirus update: Kodak federal loan in jeopardy; Gilead seeks approval of remdesivir
Top stories about how the coronavirus pandemic is affecting business around the world.
- Zacks
Regeneron's (REGN) Q2 Earnings & Sales Surpass Estimates
Regeneron (REGN) beats on Q2 earnings and sales on solid performance of Dupixent and oncology drug, Libtayo.
- Reuters
Regeneron profit beats, expects early results from COVID-19 trials in September
Regeneron is among several drugmakers racing to develop a treatment for the novel coronavirus and earlier this week said its experimental COVID-19 antibody drug combination, REGN-COV2, prevented and treated the disease in rhesus macaques and hamsters. Continued lockdowns to curb the spread of the coronavirus have prompted patients to reschedule their hospital visits, weighing on sales of physician-administered drugs such as Regeneron's blockbuster drug Eylea. U.S. sales of Eylea, approved for treating wet age-related macular degeneration, fell to $1.11 billion from $1.16 billion, but came in above Wall Street estimates of $1.06 billion, according to brokerage Piper Sandler.
